Best CAR-T CDMOs in Asia

← All CAR-T CDMOs Best Clean FDA History Commercial Scale
Region: USA Europe Asia
10
CDMOs tracked
8
Fully scored
2
With FDA records
3
FDA inspections
33
EMA/MHRA GMP certs

For Asia-manufactured car-t programs, WuXi Biologics, Minaris Advanced Therapies, and AGC Biologics lead CDMO Signal's ranking of car-t CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 31 scored car-t CDMOs to 8 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

CAR-T CDMOs manufacture engineered T-cell products, combining viral-vector transduction, T-cell activation and expansion, and rapid release testing — usually as autologous, per-patient batches on tight vein-to-vein timelines.

Choosing a CAR-T CDMO depends on autologous vs allogeneic experience, in-house vs sourced vector, closed-system processing, and chain-of-identity logistics, alongside a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 1 NAI (no action), 2 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (18), Germany (6), UNITED STATES (4), United States (3), Ireland (2).

Last updated 2026-07-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
 83.7 100.0 0 insp · 4 GMP — 0 programs
2
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
 83.5 100.0 1 insp · 6 GMP Limited 0 programs
3
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
 80.6 99.9 2 insp · 23 GMP Available 2 programs
4
GS
GenScript ProBio
Piscataway, NJ · Nanjing, CN
 79.5 100.0 — Constrained 0 programs
5
HG
Hitachi Global Life Solutions (CGT)
Yokohama, Japan
 63.0 — — — 0 programs
6
Minaris (WuXi Advanced Therapies)
Philadelphia, PA / Yokohama, Japan
 60.5 — — — 0 programs
7
TR
Takara Bio
Kusatsu, Shiga Prefecture, Japan
 59.5 — — — 8 programs
8
CTP
Cell Therapies Pty Ltd
Melbourne, Australia
 59.0 — — — 0 programs
—
Magellan Stem Cells
Sydney, Australia
 Profiled — — — 0 programs
—
Canton Biologics
Guangzhou, China
 Profiled — — — 0 programs
How we score CDMOs →

What to evaluate in a CAR-T CDMO

Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

CAR-T CDMOs — Frequently Asked Questions

Who are the top CAR-T CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked CAR-T CDMOs include WuXi Biologics, Minaris Advanced Therapies, AGC Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many CAR-T CDMOs have FDA inspection records?
CDMO Signal tracks 2 CAR-T CDMOs with FDA inspection records and 33 EMA/MHRA GMP certificates across the group.
What should I look for in a CAR-T CDMO?
Confirm vector supply (in-house or coordinated), autologous logistics and vein-to-vein turnaround, closed-system scalable processing for parallel patients, and a clean FDA and EMA/MHRA record.
Do CAR-T CDMOs make their own viral vectors?
Some produce lentiviral or retroviral vector in-house; others coordinate an external vector CDMO. In-house vector can shorten timelines and de-risk supply. Check each profile's modality coverage above.
Related modalities
Cell Therapy CDMOs Lentiviral Vector CDMOs Gene Editing CDMOs
Other Modalities
AAV Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC